Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.17.23 extracted from

  • Batlle, D.; Wysocki, J.; Satchell, K.
    Soluble angiotensin-converting enzyme 2 a potential approach for coronavirus infection therapy? (2020), Clin. Sci., 134, 543-545 .
    View publication on PubMed

Application

Application Comment Organism
medicine angiotensin-converting enzyme 2 (ACE2) fused to the Fc portion of immunoglobulin neutralizes SARS-CoV-2 in vitro. Provision of soluble recombinant human ACE2 protein can be beneficial as a novel biologic therapeutic to combat or limit infection progression caused by coronaviruses that utilize ACE2 as a receptor. If given in its soluble form as an appropriate recombinant ACE2 protein, a new tool may be at hand to combat the spread of coronavirus in susceptible individuals by limiting coronavirus attachment to the cell membranes, cell entry, and replication Homo sapiens

Localization

Localization Comment Organism GeneOntology No. Textmining
plasma membrane the full-length enzyme (ACE2) contains a structural transmembrane domain, which anchors its extracellular domain to the plasma membrane Homo sapiens 5886
-
soluble the soluble form of angiotensin-converting enzyme 2 lacks the membrane anchor and circulates in small amounts in the blood Homo sapiens
-
-

Organism

Organism UniProt Comment Textmining
Homo sapiens Q9BYF1
-
-

Source Tissue

Source Tissue Comment Organism Textmining
alveolar cell expression in type 2 pneumocytes Homo sapiens
-
blood the soluble form of angiotensin-converting enzyme 2 lacks the membrane anchor and circulates in small amounts in the blood Homo sapiens
-
gastrointestinal tract
-
Homo sapiens
-
kidney
-
Homo sapiens
-
lung low level of expression. RNA expression of angiotensin-converting enzyme 2 (ACE2) in lung AT2 cells was higher in one Asian donor as compared with white and African American donors Homo sapiens
-

Synonyms

Synonyms Comment Organism
ACE2
-
Homo sapiens

General Information

General Information Comment Organism
drug target angiotensin-converting enzyme 2 (ACE2) fused to the Fc portion of immunoglobulin neutralizes SARS-CoV-2 in vitro. Provision of soluble recombinant human ACE2 protein can be beneficial as a novel biologic therapeutic to combat or limit infection progression caused by coronaviruses that utilize ACE2 as a receptor. If given in its soluble form as an appropriate recombinant ACE2 protein, a new tool may be at hand to combat the spread of coronavirus in susceptible individuals by limiting coronavirus attachment to the cell membranes, cell entry, and replication Homo sapiens
physiological function the receptor critical for SARS-CoV entry into host cells is the angiotensin-converting enzyme 2 (ACE2). The S1 domain of the spike protein of SARS-CoV attaches the virus to its cellular receptor ACE2 on the host cells. Functionally, there are two forms of ACE2. The full-length ACE2 contains a structural transmembrane domain, which anchors its extracellular domain to the plasma membrane. The extracellular domain is a receptor for the spike (S) protein of SARS-CoV, and for the SARS-CoV-2. The soluble form of ACE2 lacks the membrane anchor and circulates in small amounts in the blood. It is proposed that this soluble form may act as a competitive interceptor of SARS-CoV and other coronaviruses by preventing binding of the viral particle to the surface-bound, full-length ACE2 Homo sapiens